Font Size

WHO

In May 2013 the Netherlands Pharmacovigilance Centre Lareb was appointed WHO Collaborating Centre for Pharmacovigilance in Education and Patient Reporting.
Lareb is the national centre for spontaneous reporting in the Netherlands. At the centre we have more than 10 years of experience in the field of patient reporting, both concerning the process and scientific evaluation thereof. Since the appointment of a chair of Pharmacovigilance at the University of Groningen in 2008, we have increasingly been involved in implementing pharmacovigilance into undergraduate curricula for medical and pharmacy students.

As a collaborating centre we want to serve as a platform for knowledge transfer by providing training, conducting research and developing best practice for staff active in pharmacovigilance, both at national centres as well as in academia. These activities will hopefully help to further develop pharmacovigilance and increase the awareness of adverse drug reactions (ADRs) and the reporting thereof.

If you have any questions please contact us via whocc@lareb.nl.

Capacity building for pharmacovigilance through education

Spontaneous reporting relies on the voluntary reporting of adverse drug reactions from health care professionals and patients. It is therefore essential that reporters gain knowledge in recognizing, managing and reporting of adverse drug reactions. For most pharmacovigilance centres, the number of health care professionals to train wildly exceeds the resources available. Choices have to be made on which group to focus. At Lareb, we have come to the conclusion that it is important to train health care professionals as early as possible in their career. It is easier to teach a student a certain behavior than to change the behavior of an older health care professional.

As a WHO Collaborating Centre we will develop and maintain a pharmacovigilance curriculum for medical, pharmacy and paramedical students.

Introducing patient reporting to pharmacovigilance was initially described as a means to decrease under-reporting rates. There is a substantial underreporting by health care professionals and targeting patients as reporters might help to increase reporting rates which in turn might speed the detection of ADRs. However the contribution of patient reporting to pharmacovigilance goes beyond a quantitative contribution. Studies have shown that patient reports have brought a new dimension to pharmacovigilance. First of all, patient provide first-hand information about the ADR, and because the lack of a professional filter, their reports can lead to better understanding of the patient's experience of an ADR.

The Netherlands Pharmacovigilance Centre Lareb has more than 10 years experience of processing patient reports. We also conduct research on the contribution of patient reports to pharmacovigilance. As a WHO Collaborating Centre we strive to share knowledge with other in order to promote patient reporting.

Conference on Patient Reporting

On April 23-24 (2015) the Netherlands Pharmacovigilance Centre Lareb, WHO Collaborating Centre for Pharmacovigilance in Education and Patient Reporting, organized the first Lareb Conference on Patient Reporting in the Dutch National Museum for the History of Science and Medicines in Leiden. The meeting attracted 60 participants from 21 countries discussing a range of subjects relating to patient reporting.

Adverse drug reaction reports of patients and Healthcare professionals - differences in reported information

Practice based training in Pharmacovigilance in GP vocational training is more effective for reporting adverse drug reactions

Experiences with adverse drug reaction reporting by patients; an 11-country survey

Are consumers ready to take part in the Pharmacovigilance system - A Portugese preliminary study concerning ADR reporting

Feedback for patients reporting adverse drug reactions; satisfaction and expectations Expert Opinion

ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems

Are patients ready to take part in the pharmacovigilance system - a Portugese preliminary study concerning drug reaction reporting

Adverse drug reaction reports of patients and Healthcare professionals; differences in reported information

Important information regarding reporting of adverse drug reactions; a qualitative study

The contribution of direct patient reporting to pharmacovigilance

The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study

Motives for reporting adverse drug reactions by patient-reporters in the Netherlands What motivates patients to report an adverse drug reaction?

Media attention and the influence on the reporting odds ratio in disproportionality analysis: an example of patient reporting of statins

Comparing patients' and Healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and the risks of statins as an example

Adverse drug reaction reporting by patients in the Netherlands - Three years of experience

Safety Monitoring of medicinal products, reporting system for the general public

Opinions of national competent authorities regarding patient reporting of adverse drug reactions

The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis

Does patient reporting lead to earlier detection of drug safety signals?

Exploring patient reported information in Signal detection within a global database

Characteristics and quality of spontaneous ADR reports submitted via the WEB-RADR app

The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015

Tailoring signal detection methodologies in a global database to focus on safety concerns reported by patients

How do Adverse Drug Reactions Influence the Patient's Daily Life? Qualitative Analysis on Spontaneous Reports by Patients